Acronym:
CA224-047
ACTRN/NCT /ethics:
NCT03470922
Scientific title:
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
Summary of trial and patient characteristics
| Cancer Type | Melanoma & other skin | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II, Phase III | Tumour Stream | Melanoma |
| Age Range | 18 years and older | Cancer Stage | Metastatic or Widespread |
| Sex | Both | Anticipated Start Date | 2018-04-10 |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II, Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Melanoma |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2018-04-10 |
| Anticipated End Date |
Trial Summary
The purpose of this study is to determine whether nivolumab in combination with relatlimab is more effective than nivolumab by itself in treating unresectable melanoma or melanoma that has spread
Lay Summary
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
Sponsor / Cooperative group
Bristol-Myers Squibb
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Dr Amitesh Roy | Recruiting |